Processa Pharmaceuticals, Inc. financial data

Symbol
PCSA on Nasdaq
Location
Vero Beach, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 292 % -52.6%
Debt-to-equity 38.7 % +96.2%
Return On Equity -301 % -54.4%
Return On Assets -217 % -33.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56.6M shares +1634%
Common Stock, Shares, Outstanding 52.9M shares +1518%
Entity Public Float 5.8M USD -43.1%
Common Stock, Value, Issued 5.29K USD +1517%
Weighted Average Number of Shares Outstanding, Basic 47.5M shares +1351%
Weighted Average Number of Shares Outstanding, Diluted 47.5M shares +1351%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
General and Administrative Expense 5.61M USD +14.6%
Operating Income (Loss) -13M USD -10.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.01M USD -15.2%
Net Income (Loss) Attributable to Parent -12.9M USD -12.2%
Earnings Per Share, Basic -1 USD/shares +71%
Earnings Per Share, Diluted -1 USD/shares +71%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.31M USD +118%
Assets, Current 6.59M USD +36.1%
Property, Plant and Equipment, Net 4.11K USD -22.6%
Operating Lease, Right-of-Use Asset 24.3K USD
Other Assets, Noncurrent 173K USD -97.8%
Assets 7.58M USD +53.5%
Accounts Payable, Current 727K USD +2.17%
Accrued Liabilities, Current 1.02M USD +148%
Liabilities, Current 1.75M USD +43.6%
Operating Lease, Liability, Noncurrent 21.8K USD -80%
Liabilities 1.75M USD +43.4%
Retained Earnings (Accumulated Deficit) -97.4M USD -15.3%
Stockholders' Equity Attributable to Parent 5.83M USD +56.8%
Liabilities and Equity 7.58M USD +53.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.73M USD -33.2%
Net Cash Provided by (Used in) Financing Activities 4.44M USD -29.2%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 52.9M shares +1516%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.71M USD -59.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.88K USD
Deferred Tax Assets, Valuation Allowance 19.9M USD +12.8%
Deferred Tax Assets, Gross 19.9M USD +12.8%
Operating Lease, Liability 21.8K USD -80%
Depreciation 301 USD +117%
Lessee, Operating Lease, Liability, to be Paid 23.3K USD -79.8%
Operating Lease, Liability, Current 21.8K USD -75%
Lessee, Operating Lease, Liability, to be Paid, Year Two 70K USD -24.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 70K USD -24.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.52K USD -76.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 889K USD +96.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares